Vol 9, No 4 (2016)
Prace poglądowe
Published online: 2016-12-28
Kwasy omega-3 a przewlekła choroba nerek — czy suplementacja jest zasadna i w jakich grupach pacjentów?
Forum Nefrologiczne 2016;9(4):223-228.
Abstract
Przewlekła choroba nerek (PChN) stanowi narastający problem wśród populacji ogólnej. U podłoża wielu jednostek chorobowych prowadzących do PChN leżą nasilony proces zapalny, stres oksydacyjny, zwiększone ciśnienie wewnątrzkłębuszkowe oraz miażdżyca. Wobec właściwości przeciwzapalnych, antyoksydacyjnych, hipotensyjnych, a także przeciwzakrzepowych kwasów omega-3 wysunięto przypuszczenie, że mogą one mieć zastosowanie w leczeniu pacjentów z chorobami nerek. Do kwasów omega-3 o największej bioaktywności należą kwasy eikozapentaenowy i dokzaheksaenowy, zawarte w tłustych rybach morskich. Niniejsza praca poglądowa ma na celu usystematyzowanie dostępnej wiedzy oraz wyników badań nad rolą kwasów omega-3 w PChN. Omówiona zostanie również zasadność ich suplementacji w wybranych jednostkach chorobowych.
Keywords: kwas eikozapentaenowykwas dokozaheksaenowyprzewlekła choroba nerek
References
- Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr. 1975; 28(9): 958–966.
- Sekikawa A, Doyle MF, Kuller LH. Recent findings of long-chain n-3 polyunsaturated fatty acids (LCn-3 PUFAs) on atherosclerosis and coronary heart disease (CHD) contrasting studies in Western countries to Japan. Trends Cardiovasc Med. 2015; 25(8): 717–723.
- Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999; 354(9177): 447–455.
- Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy. Lancet. 1984; 1(8384): 1017–1018.
- Moriyama T, Iwasaki C, Tanaka K, et al. Effects of combination therapy with renin-angiotensin system inhibitors and eicosapentaenoic acid on IgA nephropathy. Intern Med. 2013; 52(2): 193–199.
- Chou HH, Chiou YY, Hung PH, et al. Omega-3 fatty acids ameliorate proteinuria but not renal function in IgA nephropathy: a meta-analysis of randomized controlled trials. Nephron Clin Pract. 2012; 121(1-2): c30–c35.
- Ferraro PM, Ferraccioli GF, Gambaro G, et al. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant. 2009; 24(1): 156–160.
- Donadio JV, Bergstralh EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med. 1994; 331(18): 1194–1199.
- Liu LL, Wang LN. ω-3 fatty acids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Clin Nephrol. 2012; 77(2): 119–125.
- Eckardt, K.U., Kasiske B.L. KDIGO Clinical Practice Guideline for Glomerulonephritis 2012. Foreword. Kidney International Supplements. 2012; 2: 139–274.
- Prickett JD, Robinson DR, Steinberg AD. Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB x NZW F1 mice. J Clin Invest. 1981; 68(2): 556–559.
- Clark WF, Parbtani A, Naylor CD, et al. Fish oil in lupus nephritis: clinical findings and methodological implications. Kidney Int. 1993; 44(1): 75–86.
- Nakamura N, Kumasaka R, Osawa H, et al. Effects of eicosapentaenoic acids on oxidative stress and plasma fatty acid composition in patients with lupus nephritis. In Vivo. 2005; 19(5): 879–882.
- Pestka JJ, Vines LL, Bates MA, et al. Comparative effects of n-3, n-6 and n-9 unsaturated fatty acid-rich diet consumption on lupus nephritis, autoantibody production and CD4+ T cell-related gene responses in the autoimmune NZBWF1 mouse. PLoS One. 2014; 9(6): e100255.
- Chin HoJ, Fu YY, Ahn JM, et al. Omacor, n-3 polyunsaturated fatty acid, attenuated albuminuria and renal dysfunction with decrease of SREBP-1 expression and triglyceride amount in the kidney of type II diabetic animals. Nephrol Dial Transplant. 2010; 25(5): 1450–1457.
- Garman JH, Mulroney S, Manigrasso M, et al. Omega-3 fatty acid rich diet prevents diabetic renal disease. Am J Physiol Renal Physiol. 2009; 296(2): F306–F316.
- Lee CTC, Adler AI, Forouhi NG, et al. Cross-sectional association between fish consumption and albuminuria: the European Prospective Investigation of Cancer-Norfolk Study. Am J Kidney Dis. 2008; 52(5): 876–886.
- Shimizu H, Ohtani K, Tanaka Y, et al. Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. Diabetes Res Clin Pract. 1995; 28(1): 35–40.
- Hamazaki T, Takazakura E, Osawa K, et al. Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester. Lipids. 1990; 25(9): 541–545.
- Miller ER, Juraschek SP, Anderson CA, et al. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial. Diabetes Care. 2013; 36(6): 1462–1469.
- Shoji T, Kakiya R, Hayashi T, et al. Serum n-3 and n-6 polyunsaturated fatty acid profile as an independent predictor of cardiovascular events in hemodialysis patients. Am J Kidney Dis. 2013; 62(3): 568–576.
- Donnelly SM, Ali MA, Churchill DN. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. J Am Soc Nephrol. 1992; 2(11): 1634–1639.
- Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol. 1999; 10(10): 2177–2184.
- Friedman AN, Yu Z, Denski C, et al. Fatty acids and other risk factors for sudden cardiac death in patients starting hemodialysis. Am J Nephrol. 2013; 38(1): 12–18.
- Schmitz PG, McCloud LK, Reikes ST, et al. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol. 2002; 13(1): 184–190.
- Bowden RG, Wilson RL, Gentile M, et al. Effects of omega-3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. J Ren Nutr. 2007; 17(2): 126–131.
- Lok CE, Moist L, Hemmelgarn BR, et al. Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA. 2012; 307(17): 1809–1816.
- Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol. 2011; 22(5): 956–966.
- Baia LC, Van den Berg E, Vervloet MG, et al. NIGRAM consortium. Fish and omega-3 fatty acid intake in relation to circulating fibroblast growth factor 23 levels in renal transplant recipients. Nutr Metab Cardiovasc Dis. 2014; 24(12): 1310–1316.
- Fernandes MB, Caldas HC, Toloni LD, et al. Supplementation with omega-3 polyunsaturated fatty acids and experimental tacrolimus-induced nephrotoxicity. Exp Clin Transplant. 2014; 12(6): 522–527.
- Lim AKH, Manley KJ, Roberts MA, et al. Fish oil for kidney transplant recipients. Cochrane Database Syst Rev. 2007(2): CD005282.
- Miller ER, Juraschek SP, Appel LJ, et al. The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. Am J Clin Nutr. 2009; 89(6): 1937–1945.
